TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma by unknown
Chen et al. Biological Research  (2015) 48:26 
DOI 10.1186/s40659-015-0016-9RESEARCH ARTICLE Open AccessTGF-β1 expression is associated with invasion
and metastasis of intrahepatic cholangiocarcinoma
Yijie Chen1, Lin Ma2, Qian He1, Shaobo Zhang1, Chenghua Zhang1* and Wei Jia3*Abstract
Background: Transforming growth factor (TGF)-β is involved in many physiologic processes, it often promotes
metastasis, and its high expression is correlated with poor prognosis. In the present study, we analyzed the correlation
between transforming growth factor beta 1 (TGF-β1) expression and prognosis in intrahepatic cholangiocarcinoma.
Results: We examined the expression of TGF-β1 in 78 intrahepatic cholangiocarcinomas by immunohistochemistry and
correlated the expression with clinicopathological parameters. TGF-β1 was expressed in 37 of 78 (47.4 %) intrahepatic
cholangiocarcinomas. The expression of TGF-β1 was significantly correlated with lymph node metastasis, distant
metastasis, and tumour recurrence. Patients with TGF-β1-positive tumours had significantly shorter survival time.
In a multivariant analysis, the expression of TGF-β1 and the tumour stage were independent prognostic factors.
Conclusions: Our data suggest that expression of TGF-β1 is a novel prognostic marker for intrahepatic
cholangiocarcinoma.
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Intrahepatic cholangiocarcinoma (ICC) is the second most
common, primary hepatobiliary cancer after hepatocellular
carcinoma. Despite overall advances in the diagnosis and
treatment of patients with ICC, the prognosis of this dis-
ease still remains poor [1, 2]. One of the most important
factors influencing the dismal prognosis of ICC is based
on the late diagnosis at an advanced stage of disease, when
tumour cell invasion into the blood and lymphatic vessels
has resulted in metastatic spread and complete curative
resection can no longer be achieved [3]. However, the
molecular mechanisms underlying and driving metastasis
remain unclear.
Transforming growth factor (TGF)-β is involved in vari-
ous physiologic processes, such as wound healing, tissue
development, and remodelling. TGF-β has also been im-
plicated in many pathological conditions, including cancer,
and has been shown to regulate a number of critical pro-
cesses, such as angiogenesis, immune suppression, and cell* Correspondence: zchqzyy@126.com; scdxhxyy28@126.com
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creativecommons.org/publicdomain/zero/1.0/migration [4–8]. TGF-β also induces a cytostatic response
in most normal cell types and promotes metastasis in
malignant tumour cells. Furthermore, high expression of
TGF-β is correlated with poor prognosis in many malignant
tumours [9–15].
There are three known mammalian isoforms of TGF-
β, TGF-β1, −β2, and -β3, and all share significant struc-
tural and functional similarities [16]. Most malignant
tumour cells exhibit positive TGF-β1 expression, with
the most prominent expression in the plasma [14, 17].
Clinically, TGF-β1 is often elevated in the plasma of
patients with malignant tumours. Preclinically, several
models have shown correlations between TGF-β1 ex-
pression and increased tumourigenicity and increased
invasion in many malignant tumours [8–10]. In this
study, we analysed the expression of TGF-β1 in 78 ICC
cases by immunohistochemistry, and investigated the as-
sociation between TGF-β1 expression with clinicopatho-
logical parameters and patient survival.
Results
Expression of TGF-β1 protein in ICC
In normal liver tissue, TGF-β1 was not expressed in
hepatocytes or bile ducts (Fig. 1a). TGF-β1 was detected
in 37 of 78 tumours (47.4 %). Among the 37 tumoursicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Immunohistochemical staining of TGF-β1 in ICC and normal liver. a TGF-β1 is not expressed in hepatocyte or bile duct. b ICC with negative
TGF-β1 staining. c ICC with weak TGF-β1 staining. d ICC with moderate TGF-β1 cytoplasmic staining. e ICC with strong TGF-β1 cytoplasmic staining (×200)
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staining and 23 tumours had moderate to strong staining.
The tumours showed cytoplasmic staining of TGF-β1
(Fig. 1b–e). Generally, TGF-β1 expression showed consid-
erable heterogeneity in the intratumoral distribution.Clinicopathologic significance of TGF-β1 expression in ICC
To evaluate whether TGF-β1 protein was associated
with clinicopathological features of patients with ICC,
we correlated immunohistochemical TGF-β1 staining re-
sults with major clinicopathologic features of ICC. As
shown in Table 1, TGF-β1 expression was positively as-
sociated with lymph node metastasis, lymphovascular in-
vasion, distant metastasis and tumour recurrence, but
not with sex, patient age, tumour stage, and histologic
differentiation or tumour size (pT).Univariant survival analysis
In univariant survival analysis, we used the Kaplan–
Meier method to calculate the cumulative survival curve
and the differences in survival were accessed by the log-
rank method. The conventional prognostic parameters
including tumour size, nodal status, and disease stage
reached significance for the overall survival. Patients
with TGF-β1-positive tumours had a significant shorter
survival than those with TGF-β1-negative tumours
(P = 0.017; Fig. 2). The median survival of patients withTGF-β1-positive and− negative tumours was 7.3 and
16.6 months, respectively.
Multivariant survival analysis
A multivariant progression analysis based on the Cox
proportional hazard model was performed to analyse the
independent value of each parameter predicting overall
survival (Table 2). In this analysis, we included tumour
size, nodal status, disease stage, and TGF-β1 expression.
Tumour stage (P = 0.0000) and TGF-β1 expression
(P = 0.001) proved to be independent prognostic factors
for shortened overall survival in ICC.
Discussion
In this study, we demonstrate that patients with ICC
that express high levels of TGF-β1 have a higher chance
of tumour recurrence, lymph node metastasis, lympho-
vascular invasion and distant metastasis than those with
tumours that lack TGF-β1 expression. ICC is a highly
aggressive tumour with generally poor prognosis charac-
terized by intense desmoplastic stromal reaction and ex-
tensive vascular and perineural invasion.
In our series, immunohistochemical TGF-β1 expression
is an independent prognostic indicator for ICC patients ir-
respective of vascular and lymphovascular characteristics.
The high significance of our statistical data supports the
hypothesis that TGF-β1 expression may interfere with the
invasion process in ICC. TGF-β1 is an upstream effector
Table 1 TGF-β1 expression and clinicopathologic parameters of ICC
TGF-β1 expression p-value
Gender + - 0.654
Male (n = 38) 18 20
Female (n = 40) 19 21
Age 0.453
<60 years(n = 31) 17 14
≥60 years(n = 47) 20 27
Stage 0.097
I–II (n = 37) 19 18
III–IV (n = 41) 18 23
Size 0.086
T1-T2 (n = 36) 16 20
T3-T4 (n = 42) 21 21
Lymph node metastasis 0.003
Yes (n = 20) 17 3
No (n = 58) 20 38
Lymphovascular invasion 0.045
Yes (n = 16) 10 6
No (n = 62) 27 35
Distant metastasis 0.012
Yes (n = 8) 8 0
No (n = 70) 29 41
Histologic dedifferentiation 0.145
Well differentiated (n = 42) 21 21
Moderately differentiated (n = 15) 9 6
Poorly differentiated (n = 21) 7 14
Tumour recurrence 0.023
Yes(n = 47) 26 21
No(n = 31) 11 20
Fig. 2 Univariant survival analysis of TGF-β1 in all 78 ICCs demonstrates
that TGF-β1 positive tumours are associated with poor prognosis
Table 2 Multivariant survival analysis (Cox regression model)
shows TGF-β1and tumor stage are independent prognostic factor
Beta Standard error Wald df p-value
Stage 0.4973 0.1494 17.560 1 0.000
TGF-β1 0.6854 0.2981 5.853 1 0.001
Chen et al. Biological Research  (2015) 48:26 Page 3 of 5of MMPs and VEGF, which could promote invasion,
angiogenesis, and proliferation in many cancers [1–6], and
thus could be a biological predictor of survival for ICC pa-
tients [6]. However, the current understanding of invasion
and metastasis processes in ICC is poor and future studies
should focus on identification of the specific molecular
pathways involving TGF-β1 in these tumours.
The possibility of long-term survival of ICC patients
depends on early diagnosis and the feasibility of a surgi-
cal resection in cases with localized disease [18, 19]. Pa-
tients not suitable for surgery generally face rapid disease
progression with a survival rate of months according to
the series [18]. Prognostic markers are needed to identify
ICC patients with poor prognosis that might benefit from
more aggressive surgical strategies [20].
Sulkowski et al. reported a high frequency of TGF-β1
positive colorectal cancers (up to 87 % of studied cases)
with cytoplasmic accumulation both in malignant cells
and inflammatory cells. Their results suggested that
blockage of anticancer immunity is maintained by TGF-
β1 and cell growth is not restricted by TGF-β1 as much
in cancer cells as in normal intestinal epithelial cells
[21]. According to the clinical-pathological reports on
ICC, we also found that vascular invasion was a poor
prognostic predictor of early tumour recurrence in ICCs
(P < 0.05) and tumour invasion was a poor prognostic
factor only in pancreatic cancers at univariate analysis
[22]. Expression of TGF-β1 in our ICC series turned out
to be a significant predictor of survival (P = 0.017) at
univariate tests and an independent indicator of early
tumour recurrence, regardless of vascular invasion.
Conclusions
Our results indicate that TGF-β1 expression seems to
represent a specific and independent neoplastic trait of
ICC. Its immunohistochemical detection should provide
a novel biological prognostic marker for ICC.
Methods
Ethical approval
The study was approved by The 180th Hospital of People’s
Liberation Army, Quanzhou, and written informed consents
were obtained from all participants prior to study entry.
Patients
Between 2008 and 2012, 78 consecutive patients under-
went surgical resection of ICC at General Surgery
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ation Army. The group comprised 38 men and 40
women with a mean age of 64 years (range, 23.6–
78.3 years). The distribution of TNM staging was as
follows: stage I, n = 32; stage II, n = 8; stage III, n = 21,
and stage IV, n = 16. At the end of follow-up, 49 pa-
tients were dead. A total of 64 patients were followed
up at least 12 months or until death.Immunohistochemical analysis
Sections (4 μm) mounted on poly-L-lysine-coated slides
were incubated for 30 min at 60 °C, deparaffinised by
standard methods, and placed in 0.05 M Tris-HCI buf-
fer, pH 7.2. Antigen retrieval was performed for
20 min in 10 mm sodium citrate buffer (pH 6) heated
at 95 °C in a steamer, followed by cooling for 20 min.
After blocking endogenous peroxidase activity with
0.3 % aqueous hydrogen peroxide for 5 min, the pri-
mary polyclonal rabbit anti-TGF-β1 antibody (DAKO,
Carpinteria, CA, USA) was incubated with the sections
at a final dilution of 2 mg/mL for 30 min. A control
slide was incubated with Tris-HCI buffer substituted
for the primary antibody. The DAKO LSAB™ kit/HRP
was used for the detection of immunostaining. The
sections were counterstained with Mayer’s haematoxy-
lin. The staining intensity of TGF-β1 was semiquanti-
tatively scored as negative, weak or moderate/strongly
positive. A complete negative staining was scored as
negative. A weak staining was defined as a minimal but
unequivocal staining in less than 10 % of tumour cells.
Stronger or more extensive staining was scored as
moderate (10–50 %) or strong (≥50 %) positive expres-
sion. For statistical analysis, patients with weak and
moderate/strong staining were lumped together as the
TGF-β1-positive group in comparison with those with
TGF-β1-negative tumours.Statistical analysis
Statistical analysis of TGF-β1 expression between speci-
men groups was carried out using the unpaired Χ2 test.
Comparisons of clinicopathological factors (i.e. sex, age
at diagnosis, histological type, pathological stage, differ-
entiation, tumour stage, pathological stage, lymph node
metastasis and metastasis) between positive—and negative-
staining groups were performed using Χ2 tests. The
log-rank test was used to compare survival distributions
between the positive and negative staining groups, and
Kaplan–Meier curves were plotted for the two groups.
The clinical factors were accounted as being reasonable by
fitting Cox’s proportional hazards models. Differences
were considered statistically significant when the P-value
was <0.05.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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